-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Avalo Therapeutics, Inc. to Post Q4 2022 Earnings of ($0.55) Per Share, Jefferies Financial Group Forecasts (NASDAQ:AVTX)
Avalo Therapeutics, Inc. to Post Q4 2022 Earnings of ($0.55) Per Share, Jefferies Financial Group Forecasts (NASDAQ:AVTX)
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to investors on Monday, November 14th. Jefferies Financial Group analyst C. Howerton now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($2.66) per share. Jefferies Financial Group also issued estimates for Avalo Therapeutics' FY2023 earnings at ($0.54) EPS, FY2024 earnings at $0.02 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
Get Avalo Therapeutics alerts:Separately, Oppenheimer cut their price objective on shares of Avalo Therapeutics to $10.00 in a report on Tuesday.
Avalo Therapeutics Stock Performance
AVTX opened at $5.41 on Thursday. Avalo Therapeutics has a twelve month low of $2.42 and a twelve month high of $27.36. The company has a debt-to-equity ratio of 5.23, a quick ratio of 1.07 and a current ratio of 1.07. The company has a 50-day moving average price of $4.94 and a 200 day moving average price of $5.21.Institutional Investors Weigh In On Avalo Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Avalo Therapeutics during the 3rd quarter worth $52,000. Leo Brokerage LLC purchased a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Goldman Sachs Group Inc. raised its position in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after acquiring an additional 124,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after acquiring an additional 327,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $506,000.
About Avalo Therapeutics
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Read More
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) – Equities researchers at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Avalo Therapeutics in a research note issued to investors on Monday, November 14th. Jefferies Financial Group analyst C. Howerton now expects that the company will earn ($0.55) per share for the quarter, down from their previous estimate of $0.06. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($2.66) per share. Jefferies Financial Group also issued estimates for Avalo Therapeutics' FY2023 earnings at ($0.54) EPS, FY2024 earnings at $0.02 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.10) EPS.
阿瓦洛治疗公司(纳斯达克：AVTX-GET评级)--杰富瑞金融集团的股票研究人员在11月14日星期一发布给投资者的一份研究报告中下调了他们对阿瓦洛治疗公司2022年第四季度每股收益的估计。杰富瑞金融集团分析师C.Howerton现在预计，该公司本季度每股收益为0.55美元，低于此前预测的0.06美元。对Avalo治疗公司目前全年收益的普遍估计为每股2.66美元。杰富瑞金融集团还发布了对Avalo Treateutics 2023财年每股收益为0.54美元、2024财年每股收益为0.02美元、2025财年每股收益为0.14美元和2026财年每股收益为0.10美元的预期。
Separately, Oppenheimer cut their price objective on shares of Avalo Therapeutics to $10.00 in a report on Tuesday.
另外，奥本海默在周二的一份报告中将Avalo治疗公司股票的目标价下调至10.00美元。
Avalo Therapeutics Stock Performance
Avalo治疗公司股票表现
Institutional Investors Weigh In On Avalo Therapeutics
机构投资者看好Avalo治疗公司
Hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. purchased a new position in Avalo Therapeutics during the 3rd quarter worth $52,000. Leo Brokerage LLC purchased a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Goldman Sachs Group Inc. raised its position in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after acquiring an additional 124,769 shares during the last quarter. Renaissance Technologies LLC raised its position in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after acquiring an additional 327,241 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth about $506,000.
对冲基金和其他机构投资者最近调整了对该公司的持股。Assenagon Asset Management S.A.在第三季度购买了Avalo Treeutics的一个新头寸，价值5.2万美元。Leo Brokerage LLC在第一季度购买了Avalo治疗公司的新股份，价值约4.5万美元。第二季度，高盛公司将其在阿瓦洛治疗公司的持股比例提高了23.8%。高盛股份有限公司在上个季度增持了124,769股后，目前持有649,653股该公司股票，价值324,000美元。复兴技术公司在第一季度将其在阿瓦洛治疗公司的地位提高了819.1%。复兴科技有限责任公司在上个季度增持了327,241股后，现在拥有367,193股该公司股票，价值266,000美元。最后，Millennium Management LLC在第二季度获得了Avalo治疗公司的一个新头寸，价值约506,000美元。
About Avalo Therapeutics
关于Avalo Treateutics
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics，Inc.是一家临床阶段的精密药物公司，为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002，这是一种完全人类抗光的单抗，正在进行第二阶段临床试验，用于治疗非嗜酸性哮喘以及炎症性肠道疾病，包括中到重度克罗恩病和溃疡性结肠炎；以及第三阶段临床试验，用于治疗新冠肺炎急性呼吸窘迫综合征。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- ASML的11月拉力赛有后劲吗？
- Verra移动库存已返回空间站
- 在盈利暴跌后，Advance Auto Parts是一笔买入吗？
- BJ‘s批发俱乐部：当心卖方
- 马伦汽车股票的下一个催化剂是12月23日
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧